Shopping Cart is Empty..

$ 0

Swine Health Market by Disease (Aujeszkys Disease (AD), Classical Swine Fever (CSF), Actinobacillus Pleuropneumonia, Mycoplasma Hyopneumoniae, Swine Enteric Coronavirus Disease, Porcine Reproductive and Respiratory Syndrome (PRRS), and Salmonella) and by Route of Administration (Injectable and Oral) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Pharmaceuticals	LI 173521	Pages: NA	Formats*:
Oct 2017 \| 84 Views	Charts: NA	Tables: NA	Author(s): NA

Swine health is associated with the diseases caused due to pigs and the development of therapeutics to prevent the related ailments and disorders. Pig breeding can lead to many diseases such as reproductive disease and congenital malformations. Hence, governmental organizations are launching programs to protect and enhance the health of swine, which reduces the effect of swine diseases on humans.

Increase in incidences of diseases through swine drive the market. However, high cost associated with swine health especially in the developing countries impede the market growth. Moreover, key market players investing in R&D activities to develop novel therapeutics to address unmet medical needs create lucrative opportunities.

Swine health market is segmented based on diseases, route of administration, and geography. Based on diseases, the market is divided into aujeszkys disease (AD), classical swine fever (CSF), actinobacillus pleuropneumonia, mycoplasma hyopneumoniae, swine enteric coronavirus disease, porcine reproductive and respiratory syndrome (PRRS), and salmonella. Based on route of administration, the market is classified into injectable and oral. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Comprehensive competitive analysis and profiles of major market players such as Neogen Co, Norbrook Group, Orion Pharma, Phibro Animal Health, Vetoquinol Animal Health Pvt Ltd, Bio-Vet, Dechra Pharmaceuticals PLC, ECO Animal Health, Huvepharma SEA Private Limited, and Indian Immunologicals are provided in this report.

Key Benefits

This report provides an extensive analysis of the current and emerging market trends and dynamics in the global swine health market.
In-depth analysis is conducted by constructing market estimations for key market segments between 2017 and 2023.
This study that evaluates the competitive landscape and value chain is taken into account to help understand the competitive environment globally.
Comprehensive analysis of factors that drive and restrict the growth of the global swine health market is provided.
This report provides the quantitative analysis of the current market and estimations from 2017-2023, which assists in identifying prevailing market opportunities
Comprehensive analysis of all regions is provided that determines prevailing opportunities in these regions.

Swine Health Market Key Segments:

By Disease

Aujeszky's Disease (AD)
Classical Swine Fever (CSF)
Actinobacillus Pleuropneumonia
Mycoplasma Hyopneumoniae
Swine Enteric Coronavirus Disease
Porcine Reproductive and Respiratory Syndrome (PRRS)
Salmonella

By Route of Administration

Injectable
Oral

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- UK
- France
- Germany
- Spain
- Rest of Europe
Asia-Pacific
- China
- India
- Australia
- Japan
- Rest of Asia-Pacific
LAMEA
- Brazil
- Turkey
- Saudi Arabia
- South Africa
- Rest of LAMEA

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

License Type

Data Pack

Single User PDF

Five User Online/PDF

Enterprise Online/PDF

LICENSE INFO

Users/Sharing

Restricted to one authorized user

Limited to 5 authorized users

Unlimited within company / enterprise

Printing

One Print only

Up to Five Copies

Unlimited within company / enterprise

Delivery Formats

ADDED BENIFITS

20% Free customization (Pre-sale)

16 Analyst hour support (Post Sale)

40 Analyst hour support (Post Sale)

160 hours of mini-consult

Free quarterly industry update

Free report on update (within 180 days)

MULTIPLE PURCHASE

Complimentary report with 2 reports

Complimentary report with 3 reports

Subscription Model

Have questions ?
Speak with analyst

Did you miss anything?
To add more

* Taxes/Fees, If applicable, will be
added at the checkout. All prices in USD.

Need More Information

+1-503-894-6022

help@alliedmarketresearch.com

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

Targeted Market View

Targeted market view to eliminate redundant information to provide valued information and save time of the reader

Get fresh content delivered

Get insights on topics that matter to your business. Stay updated on the areas that interest you.

Report Title: Swine Health Market by Disease (Aujeszkys Disease (AD), Classical Swine Fever (CSF), Actinobacillus Pleuropneumonia, Mycoplasma Hyopneumoniae, Swine Enteric Coronavirus Disease, Porcine Reproductive and Respiratory Syndrome (PRRS), and Salmonella) and by Route of Administration (Injectable and Oral) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Select Chapters

Chapter 1 Chapter 2 Chapter 3 Chapter 4 Chapter 5 Chapter 6 Chapter 7

Full Name: *:

Company Name: *:

Job Role: *:

Email: *:

Country: *:

Contact Number: *:

How can we help? *:

Security Code: *:

STAY WITH US

WE ACCEPT

* Pricing on the website is provided for single users licenses only. All reports will be provided in a PDF format for download. To purchase multi-user licenses, please contact us at +1-800-792-5285 or send an email to sales@alliedmarketresearch.com
Chapter: 1 INTRODUCTION 1.1. REPORT DESCRIPTION 1.2. KEY BENEFITS 1.3. KEY MARKET SEGMENTS 1.4. RESEARCH METHODOLOGY 1.4.1. Secondary research 1.4.2. Primary research 1.4.3. Analyst tools & models
Chapter: 2 EXECUTIVE SUMMARY 2.1. CXO PERSPECTIVE
Chapter: 3 MARKET OVERVIEW 3.1. MARKET DEFINITION AND SCOPE 3.2. KEY FINDINGS 3.2.1. Top investment pockets 3.2.2. Top winning strategies 3.3. MARKET SHARE ANALYSIS/TOP PLAYER POSITIONING, 2016 3.4. PORTER’S FIVE FORCES ANALYSIS 3.5. MARKET DYNAMICS 3.5.1. Drivers 3.5.2. Restraints 3.5.3. Opportunities
Chapter: 4 SWINE HEALTH MARKET, BY DISEASE 4.1. OVERVIEW 4.1.1. Market size and forecast 4.2. AUJESZKY'S DISEASE (AD) 4.2.1. Key market trends 4.2.2. Growth factors and opportunities 4.2.3. Market size and forecast 4.3. CLASSICAL SWINE FEVER (CSF) 4.3.1. Key market trends 4.3.2. Growth factors and opportunities 4.3.3. Market size and forecast 4.4. ACTINOBACILLUS PLEUROPNEUMONIA 4.4.1. Key market trends 4.4.2. Growth factors and opportunities 4.4.3. Market size and forecast 4.5. MYCOPLASMA HYOPNEUMONIAE 4.5.1. Key market trends 4.5.2. Growth factors and opportunities 4.5.3. Market size and forecast 4.6. SWINE ENTERIC CORONAVIRUS DISEASE 4.6.1. Key market trends 4.6.2. Growth factors and opportunities 4.6.3. Market size and forecast 4.7. PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME (PRRS) 4.7.1. Key market trends 4.7.2. Growth factors and opportunities 4.7.3. Market size and forecast 4.8. SALMONELLA 4.8.1. Key market trends 4.8.2. Growth factors and opportunities 4.8.3. Market size and forecast
Chapter: 5 SWINE HEALTH MARKET, BY ROUTE OF ADMINISTRATION 5.1. OVERVIEW 5.1.1. Market size and forecast 5.2. INJECTABLE 5.2.1. Key market trends 5.3. ORAL 5.3.1. Key market trends
Chapter: 6 SWINE HEALTH MARKET, BY REGION 6.1. OVERVIEW 6.2. NORTH AMERICA 6.2.1. Key market trends 6.2.2. Key growth factors and opportunities 6.2.3. Market size and forecast 6.2.3.1. U.S. market size and forecast 6.2.3.2. Canada market size and forecast 6.2.3.3. Mexico market size and forecast 6.2.4. North America Swine Health Market by Disease 6.2.5. North America Swine Health Market by Route of Administration 6.3. EUROPE 6.3.1. Key market trends 6.3.2. Key growth factors and opportunities 6.3.3. Market size and forecast 6.3.3.1. Germany market size and forecast 6.3.3.2. France market size and forecast 6.3.3.3. UK market size and forecast 6.3.3.4. Spain market size and forecast 6.3.3.5. Rest of Europe market size and forecast 6.3.4. Europe Swine Health Market by Disease 6.3.5. Europe Swine Health Market by Route of Administration 6.4. ASIA-PACIFIC 6.4.1. Key market trends 6.4.2. Key growth factors and opportunities 6.4.3. Market size and forecast 6.4.3.1. Japan market size and forecast 6.4.3.2. China market size and forecast 6.4.3.3. Australia market size and forecast 6.4.3.4. India market size and forecast 6.4.3.5. Rest of Asia-Pacific market size and forecast 6.4.4. Asia-Pacific Swine Health Market by Disease 6.4.5. Asia-Pacific Swine Health Market by Route of Administration 6.5. LAMEA 6.5.1. Key market trends 6.5.2. Key growth factors and opportunities 6.5.3. Market size and forecast 6.5.3.1. Brazil market size and forecast 6.5.3.2. Turkey market size and forecast 6.5.3.3. Saudi Arabia market size and forecast 6.5.3.4. South Africa market size and forecast 6.5.3.5. Rest of LAMEA market size and forecast 6.5.4. LAMEA Swine Health Market by Disease 6.5.5. LAMEA Swine Health Market by Route of Administration
Chapter: 7 COMPANY PROFILES 7.1. NEOGEN CO 7.1.1. Operating business segments 7.1.2. Business performance 7.1.3. Key strategic moves and developments 7.2. NORBROOK GROUP 7.2.1. Operating business segments 7.2.2. Business performance 7.2.3. Key strategic moves and developments 7.3. ORION PHARMA 7.3.1. Operating business segments 7.3.2. Business performance 7.3.3. Key strategic moves and developments 7.4. PHIBRO ANIMAL HEALTH 7.4.1. Operating business segments 7.4.2. Business performance 7.4.3. Key strategic moves and developments 7.5. VETOQUINOL ANIMAL HEALTH PVT LTD 7.5.1. Operating business segments 7.5.2. Business performance 7.5.3. Key strategic moves and developments 7.6. BIO-VET 7.6.1. Operating business segments 7.6.2. Business performance 7.6.3. Key strategic moves and developments 7.7. DECHRA PHARMACEUTICALS PLC 7.7.1. Operating business segments 7.7.2. Business performance 7.7.3. Key strategic moves and developments 7.8. ECO ANIMAL HEALTH 7.8.1. Operating business segments 7.8.2. Business performance 7.8.3. Key strategic moves and developments 7.9. HUVEPHARMA SEA PRIVATE LIMITED 7.9.1. Operating business segments 7.9.2. Business performance 7.9.3. Key strategic moves and developments 7.10. INDIAN IMMUNOLOGICALS 7.10.1. Operating business segments 7.10.2. Business performance 7.10.3. Key strategic moves and developments

Purchase Options